Morias S, et al. – Researchers conducted this integrative review to study stereotactic ablative radiation therapy (SABR)-related normal tissue toxicities reported in the literature. Based on published clinical trials and tumor location (central or peripheral tumors) for available SABR techniques, they summarized the toxicities reported in literature. They used clinical reports to compile adverse events, owing to the lack of clinical studies reporting on the statistical significance (eg, P-values and confidence intervals) of the toxicities experienced by patients. Findings demonstrated that it is safe to use SABR for the treatment of lung cancer. Increased procedure-related morbidity was observed in relation to surgery, in phase 3 trials comparing lobectomy and SABR. In addition, SABR-related high-grade toxicities/fatalities were evident in very few studies in phase 2 trials.